A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Overview of attention for article published in Clinical Cancer Research, March 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog
twitter: 9 X users

patent: 96 patents
weibo: 1 weibo user
facebook: 1 Facebook page

Readers on

mendeley: 599 Mendeley

So far, Altmetric has seen 96 patents that reference this research output.

T cell receptors and methods of use thereof

Grant US-12692296-B2

United States of America

28 Jul 2026

Anti-DLL3 antibodies and methods of use

Grant US-12686725-B2

United States of America

21 Jul 2026

Methods of isolating T cells and T cell receptors having antigenic specificity for a…

Grant US-12630802-B2

United States of America

19 May 2026

Composition of NY-ESO-1-specific t cell receptors restricted on multiple major…

Grant US-12617834-B2

United States of America

05 May 2026

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 92 additional patents.